Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 14, 2023
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE TrialsWout W A van den Broek, Nabil Mani, Jaouad Azzahhafi, et al.Nederlands Tijdschrift Voor Geneeskunde|February 9, 2022
[Genotype-guided antithrombotic therapy]Wout W A van den Broek, Jaouad Azzahhafi, Ron H N van Schaik, et al.Nederlands Tijdschrift Voor Geneeskunde|June 23, 2022
[Recent developments in secondary cardiovascular prevention: the pros and cons of dual pathway inhibition]Michael J Nugteren, Gert J de Borst, Wout W A van den Broek, et al.European Heart Journal. Cardiovascular Pharmacotherapy|June 20, 2022
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndromeWout W A van den Broek, Jacqueline G van Paassen, Marieke E Gimbel, et al.Journal of Cardiovascular Pharmacology and Therapeutics|October 30, 2023
The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS RegistryJaouad Azzahhafi, Wout W A van den Broek, Dean R P P Chan Pin Yin, et al.Journal of the American College of Cardiology|September 11, 2024
Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the WeekWout W A van den Broek, Brenden S Ingraham, Naveen L Pereira, et al.Journal of the American Heart Association|May 6, 2026
2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 GenotypingLarisa H Cavallari, Craig R Lee, Amber L Beitelshees, et al.Frontiers in Pharmacology|December 22, 2022
Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-studyJaouad Azzahhafi, Thomas O Bergmeijer, Wout W A van den Broek, et al.Journal of the American Heart Association|March 7, 2022
Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy PatientsAnne G Raafs, Andrea Boscutti, Michiel T H M Henkens, et al.JACC. Cardiovascular Interventions|February 11, 2026
Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular GeneticsMattia Galli, Naveen L Pereira, Ryan J Lennon, et al.Pageof 2